PLSH
Price
$0.07
Change
+$0.01 (+16.67%)
Updated
Sep 25 closing price
Capitalization
1.21M
STEK
Price
$0.01
Change
-$0.00 (-0.00%)
Updated
Sep 25 closing price
Capitalization
2.27M
Interact to see
Advertisement

PLSH vs STEK

Header iconPLSH vs STEK Comparison
Open Charts PLSH vs STEKBanner chart's image
Panacea Life Sciences Holdings
Price$0.07
Change+$0.01 (+16.67%)
Volume$7.14K
Capitalization1.21M
Stemtech
Price$0.01
Change-$0.00 (-0.00%)
Volume$246.84K
Capitalization2.27M
PLSH vs STEK Comparison Chart in %
Loading...
PLSH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PLSH vs. STEK commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PLSH is a StrongBuy and STEK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (PLSH: $0.06 vs. STEK: $0.01)
Brand notoriety: PLSH and STEK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: PLSH: 209% vs. STEK: 101%
Market capitalization -- PLSH: $1.21M vs. STEK: $1.91M
PLSH [@Pharmaceuticals: Generic] is valued at $1.21M. STEK’s [@Pharmaceuticals: Generic] market capitalization is $1.91M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PLSH’s FA Score shows that 1 FA rating(s) are green whileSTEK’s FA Score has 0 green FA rating(s).

  • PLSH’s FA Score: 1 green, 4 red.
  • STEK’s FA Score: 0 green, 5 red.
According to our system of comparison, PLSH is a better buy in the long-term than STEK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PLSH’s TA Score shows that 4 TA indicator(s) are bullish while STEK’s TA Score has 4 bullish TA indicator(s).

  • PLSH’s TA Score: 4 bullish, 3 bearish.
  • STEK’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PLSH is a better buy in the short-term than STEK.

Price Growth

PLSH (@Pharmaceuticals: Generic) experienced а -12.31% price change this week, while STEK (@Pharmaceuticals: Generic) price change was +5.31% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.18%. For the same industry, the average monthly price growth was +24.24%, and the average quarterly price growth was +67.33%.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.18% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STEK($2.27M) has a higher market cap than PLSH($1.21M). PLSH YTD gains are higher at: 128.000 vs. STEK (-66.523). STEK has higher annual earnings (EBITDA): -1.67M vs. PLSH (-2.87M). STEK has more cash in the bank: 272K vs. PLSH (243K). STEK has less debt than PLSH: STEK (4.14M) vs PLSH (11.3M). PLSH has higher revenues than STEK: PLSH (4.14M) vs STEK (3.91M).
PLSHSTEKPLSH / STEK
Capitalization1.21M2.27M53%
EBITDA-2.87M-1.67M171%
Gain YTD128.000-66.523-192%
P/E RatioN/AN/A-
Revenue4.14M3.91M106%
Total Cash243K272K89%
Total Debt11.3M4.14M273%
FUNDAMENTALS RATINGS
PLSH vs STEK: Fundamental Ratings
PLSH
STEK
OUTLOOK RATING
1..100
342
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
40
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3997
P/E GROWTH RATING
1..100
2691
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STEK's Valuation (40) in the null industry is in the same range as PLSH (41). This means that STEK’s stock grew similarly to PLSH’s over the last 12 months.

STEK's Profit vs Risk Rating (100) in the null industry is in the same range as PLSH (100). This means that STEK’s stock grew similarly to PLSH’s over the last 12 months.

STEK's SMR Rating (97) in the null industry is in the same range as PLSH (100). This means that STEK’s stock grew similarly to PLSH’s over the last 12 months.

PLSH's Price Growth Rating (39) in the null industry is somewhat better than the same rating for STEK (97). This means that PLSH’s stock grew somewhat faster than STEK’s over the last 12 months.

PLSH's P/E Growth Rating (26) in the null industry is somewhat better than the same rating for STEK (91). This means that PLSH’s stock grew somewhat faster than STEK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PLSHSTEK
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PLSH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STEK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CSTM15.330.37
+2.47%
Constellium SE
CDE18.440.24
+1.32%
Coeur Mining
PTLO6.320.02
+0.32%
Portillo's
CAPN10.47N/A
N/A
Cayson Acquisition Corp
ADTX0.84-0.01
-1.08%
Aditxt Inc

STEK and

Correlation & Price change

A.I.dvisor tells us that STEK and CNADF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that STEK and CNADF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STEK
1D Price
Change %
STEK100%
+18.32%
CNADF - STEK
25%
Poorly correlated
N/A
BFRI - STEK
12%
Poorly correlated
-0.02%
HLNCF - STEK
11%
Poorly correlated
-3.57%
PLSH - STEK
8%
Poorly correlated
-13.64%
EAPIF - STEK
6%
Poorly correlated
N/A
More